Decipher Bladder Test for Providers

Decipher Bladder provides deep biological insight into a patient’s bladder cancer to help guide personalized treatment decisions.

How to Order Sample Report
Cancer area illustration

Supported by clinical studies and peer-reviewed publications

4.3K

Bladder cancer patients included in published studies with Decipher Bladder1

>19

Peer-reviewed publications demonstrating the clinical validity and utility of Decipher Bladder1

>15

Ongoing analyses of prospective trials1

glowing divider
How to Order View Sample Report View FAQs

Understanding the Decipher Bladder test

  • Decipher Bladder classifies bladder tumors by molecular subtype.
  • Based on the expression of 219 genes, the test provides a deep biological characterization of the bladder cancer.
  • The test is performed on tumor tissue collected during a transurethral resection of bladder tumor (TURBT).
  • Decipher Bladder is intended for patients with clinical stage T1 to T4a bladder cancer. 

How Decipher Bladder may help

Decipher Bladder is a molecular subtyping tool that identifies patients who are more likely to progress, be upstaged, and benefit from certain therapies.

A diagram comparing Luminal and Non-luminal subtypes of a medical condition. The left column, titled "Luminal subtypes" in blue, lists "Better outcomes" (lower upstaging/mortality, better survival) and "Therapy response" (less benefit from NAC, IO, and chemo-IO), with a single box below labeled "Luminal". The right column, titled "Non-luminal subtypes" in orange, lists "Less favorable outcomes" (higher upstaging/mortality) and "Therapy response" (greater benefit from NAC, IO, and chemo-IO). Below this are four boxes labeled "Infiltrated", "Basal", "Basal Claudin-Low" (with a note about greatest benefit from IO and chemo-IO), and "Neuroendocrine-Like" (with a note about being the most aggressive subtype with chemoradiation benefit).

How to order the Decipher Bladder test

Once the Decipher Bladder test has been ordered by a clinician, Veracyte will request the patient’s tissue.

Documents required to place an order

Online orders

The Decipher portal is an online tool that enables you to place, track order status, and view order results.

Visit our Decipher portal and login.

Request a new Decipher portal account: Please fill out the contact us form and a representative will reach out to you.

Fax and email orders

If your practice does not have a Decipher portal account, you may also send the completed requisition form via email or fax.

[email protected]

+1-858-766-6575

Medicare and insurance coverage for Decipher Bladder

Decipher Bladder is covered by Medicare for patients with clinical stage T1-T4a bladder cancer. Financial support may be available to eligible patients.

Medicare Coverage Patient Financial Assistance

Decipher sample report

The Decipher Bladder report provides the molecular subtype of a patient’s tumor and language that helps interpret:

  • How the subtype impacts disease prognosis
  • Likelihood of upstaging
  • Benefit from receiving neoadjuvant chemotherapy (NAC)
Download Sample Report
Decipher Bladder Sample report

Frequently Asked Questions

View All FAQs

Keep exploring

Scientific Publications

Veracyte publications and references showcasing discoveries and advancements.

Explore

Provider Resource Center

View scientific publications, videos, FAQS, and more.

Explore

Events

Meet with us and discuss how we support clinicians.

Learn More

Technology and Pipeline

Explore our portfolio of molecular tests, developments, and progress.

Discover

Connect with us

Contact Us

References

  1. Company data on file as of February 17, 2026.
  2. de Jong, J.J. et al. Eur Urol Open Sci. 2025. DOI: 10.1016/j.euros.2024.12.009
  3. Lotan, Y. et al. Eur Urol. 2019. DOI: 10.1016/j.eururo.2019.04.036
  4. Seiler, R. et al. Eur Urol. 2017. DOI: 10.1016/j.eururo.2017.03.030
  5. Lotan, Y. et al. J Urol. 2022. DOI: 10.1097/JU.0000000000002261
  6. Basile, D.P. et al. Clin Cancer Res. 2022. DOI: 10.1158/1078-0432.CCR-22-2158
  7. Reike, M.J. et al. Clin Genitourin Cancer. 2024. DOI: 10.1016/j.clgc.2024.102214
  8. Necchi, A. et al. Eur Urol. 2021. DOI: 10.1016/j.eururo.2021.03.014
  9. Bandini, M. et al. Ann Oncol. 2020. DOI: 10.1016/j.annonc.2020.09.011
  10. Necchi, A. et al. Eur Urol. DOI: 10.1016/j.eururo.2020.02.028
  11. Gupta, S. et al. J Clin Oncol. 2022. DOI: 10.1200/JCO.2022.40.6_suppl.528
  12. Mercinelli, C. et al. J Clin Oncol. 2025. DOI: 10.1200/JCO.2025.43.16_suppl.4594
  13. Grivas, P. et al. Urol Oncol. 2020. DOI: 10.1016/j.urolonc.2019.11.004
  14. Batista da Costa, J. et al. Clin Cancer Res. 2019. DOI: 10.1158/1078-0432.CCR-18-3558

Disclaimers

Decipher testing is available in the United States as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service, and FDA clearance is not required.

Talk to your doctor about whether Veracyte tests might be right for you.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.